Technology Innovation Institute’s Directed Energy Research Centre becomes First-in-Region to Replicate Electromagnetic Pulses from High-altitude Nuclear Reaction
18.10.2021 12:28:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Centre (DERC) has become the first such entity in the region capable of reproducing the high-altitude electromagnetic pulses (HEMP) generated during nuclear reaction in high altitudes at its electromagnetic compatibility (EMC) labs. The Nuclear Electromagnetic Pulse Simulator offers critical infrastructures, service providers, and research institutions in the UAE and wider GCC region greater autonomy when it comes to testing - a function that needed to earlier be outsourced abroad.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005404/en/
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (Photo: AETOSWire)
DERC’s EMC labs comprise a modular semi-anechoic chamber that enables testing to evaluate susceptibility of electronics to electromagnetic pulses while providing the necessary evidence that these comply with international standards.
In partnership with Montena Technologies, a leading Switzerland-based company specialising in the generation and measurement of high-voltage fast transient impulses, simulating natural and human-made electromagnetic phenomena, and a key manufacturer of Nuclear EMP systems, DERC has commissioned a system to replicate the electromagnetic environment generated by a nuclear reaction at high altitudes (more than 40 km above the ground) in the laboratory.
Speaking on the development, Dr. Ray O. Johnson, CEO of Technology Innovation Institute (TII), said: “In line with our ambition to continue to develop breakthrough solutions that drive IP development and facilitate cutting-edge scientific research, this new capability is important. As a leading technology institute in the region, we are committed to building the UAE’s science, technology, and engineering prowess, while leveraging the power of advanced technologies to make our world more secure.”
Dr Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (DERC), said: “We are delighted to add this capability to DERC’s growing resources of cutting-edge technological solutions that are shaping our future. A Nuclear Electromagnetic Pulse simulator is unique to the GCC region and is crucial for the protection of strategic systems and critical infrastructures.”
DERC and TII can now offer government entities and industry in the UAE, the requisite experimental, numerical, and analytical support to verify accurate hardening of equipment against multiple international standards.
Manufacturers keen to export their products to markets compliant with EMC directives (namely the EU or the United States) and those conforming to IEC requirements on HEMP protection will appreciate the significance of this announcement.
For his part, Werner Hirschi, CEO, Montena Technologies SA, said: “As a global leader in providing equipment for simulation of electromagnetic threats, for the measurement of pulsed electromagnetic quantities and for the transmission of fast pulsed signals in noisy environments, we are pleased to partner with DERC in implementing a unique infrastructure that will trigger the impulse to success. Montena looks forward to a long and fruitful collaboration with TII and is committed to supporting TII in meeting its goal of creating innovation for a better world.”
For more information, visit
www.tii.ae
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter:
https://twitter.com/TIIuae
Instagram:
https://www.instagram.com/tiiuae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005404/en/
Contact information
Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom